Abstract
Design of inhibitors of P-glycoprotein still represents a challenging task for medicinal chemists. The polyspecificity of the transporter combined with the limited structural information renders rational drug design approaches rather ineffective. Within this article we will exemplify how recent insights into structure and mechanism of Pglycoprotein may aid in design of potent inhibitors. P >
Keywords: Cyclic peptide P-glycoprotein inhibitor, ATP-binding cassette, Nucleotide binding domain, Transmembrane domain, Central nervous system, Blood brain barrier, Breast cancer related protein, Positron emission tomography, Single-photon emission computed tomography, Cytochrome P450-3A4, Multidrug resistance, MDR, Protein-ligand interaction fingerprints, Serotonine reuptake transporter, Dopamine transporter, Norepinephrine transporter, Structure activity relationship, Radiolabeled P-gp substrates, SAV1866, Ligand docking, Quinazolinones, GABAA receptor, Pharmacophore modeling, NCI-60 screening, ATPbinding site, Tyrosine kinases (TKs), Nilotinib, Dasatinib, Bosutinib, ATPases
Current Topics in Medicinal Chemistry
Title: Using Structural and Mechanistic Information to Design Novel Inhibitors/Substrates of P-Glycoprotein
Volume: 10 Issue: 17
Author(s): Freya Klepsch, Thomas Stockner, Thomas Erker, Markus Muller, Peter Chiba and Gerhard F. Ecker
Affiliation:
Keywords: Cyclic peptide P-glycoprotein inhibitor, ATP-binding cassette, Nucleotide binding domain, Transmembrane domain, Central nervous system, Blood brain barrier, Breast cancer related protein, Positron emission tomography, Single-photon emission computed tomography, Cytochrome P450-3A4, Multidrug resistance, MDR, Protein-ligand interaction fingerprints, Serotonine reuptake transporter, Dopamine transporter, Norepinephrine transporter, Structure activity relationship, Radiolabeled P-gp substrates, SAV1866, Ligand docking, Quinazolinones, GABAA receptor, Pharmacophore modeling, NCI-60 screening, ATPbinding site, Tyrosine kinases (TKs), Nilotinib, Dasatinib, Bosutinib, ATPases
Abstract: Design of inhibitors of P-glycoprotein still represents a challenging task for medicinal chemists. The polyspecificity of the transporter combined with the limited structural information renders rational drug design approaches rather ineffective. Within this article we will exemplify how recent insights into structure and mechanism of Pglycoprotein may aid in design of potent inhibitors. P >
Export Options
About this article
Cite this article as:
Klepsch Freya, Stockner Thomas, Erker Thomas, Muller Markus, Chiba Peter and F. Ecker Gerhard, Using Structural and Mechanistic Information to Design Novel Inhibitors/Substrates of P-Glycoprotein, Current Topics in Medicinal Chemistry 2010; 10 (17) . https://dx.doi.org/10.2174/156802610792928004
DOI https://dx.doi.org/10.2174/156802610792928004 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Biologicals Dramatic Advances in the Treatment of Psoriasis
Current Pharmaceutical Design Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design On the Physiological Relevance of Muscarinic Acetylcholine Receptors in Alzheimers Disease
Current Medicinal Chemistry Oligonucleotide-Based Molecular Therapy for Restenosis after Angioplasty
Current Drug Targets Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation
Current Drug Delivery A Fatal Case of Acute Interstitial Pneumonia (AIP) in a Woman Affected by Glioblastoma
Current Drug Safety New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia
Current Drug Therapy The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry The Use of Novel Oral Anticoagulants in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Perspectives on Therapeutic Target for Multiple System Atrophy
Recent Patents on Regenerative Medicine Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Synthesis and Spectral Study of Some Novel Oxime Esters Derived from 3-azabicyclo[3.3.1]nonan-9-one Oxime
Letters in Organic Chemistry The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Glucocorticoid Receptor Antagonists
Current Topics in Medicinal Chemistry N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Amniotic Fluid Embolism: What Level of Scientific Evidence can be Drawn? A Systematic Review
Current Pharmaceutical Biotechnology